NOVO.B.DK

239.3

+0.04%↑

GMAB.DK

1,845

+0.49%↑

HLUNB.DK

39.12

+0.05%↑

AMBUB.DK

78.5

+0.71%↑

NOVO.B.DK

239.3

+0.04%↑

GMAB.DK

1,845

+0.49%↑

HLUNB.DK

39.12

+0.05%↑

AMBUB.DK

78.5

+0.71%↑

NOVO.B.DK

239.3

+0.04%↑

GMAB.DK

1,845

+0.49%↑

HLUNB.DK

39.12

+0.05%↑

AMBUB.DK

78.5

+0.71%↑

NOVO.B.DK

239.3

+0.04%↑

GMAB.DK

1,845

+0.49%↑

HLUNB.DK

39.12

+0.05%↑

AMBUB.DK

78.5

+0.71%↑

NOVO.B.DK

239.3

+0.04%↑

GMAB.DK

1,845

+0.49%↑

HLUNB.DK

39.12

+0.05%↑

AMBUB.DK

78.5

+0.71%↑

Search

Coloplast A-S (Class B)

Avatud

475.6 -1.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

471.8

Max

483.9

Põhinäitajad

By Trading Economics

Sissetulek

522M

1.4B

Müük

83M

7B

P/E

Sektori keskmine

27.754

108.767

Aktsiakasum

6.32

Dividenditootlus

4.78

Kasumimarginaal

19.835

Töötajad

16,983

EBITDA

309M

2.3B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.78%

2.21%

Järgmine tulemuste avaldamine

12. mai 2026

Järgmine dividendimakse kuupäev

20. mai 2026

Järgmine aktsia dividendi kuupäev (ex-date)

18. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-7.8B

111B

Eelmine avamishind

476.85

Eelmine sulgemishind

475.6

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2026, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25. veebr 2026, 23:15 UTC

Tulu

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25. veebr 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25. veebr 2026, 23:47 UTC

Tulu

Ferrovial 4Q Net EUR197M >FER.MC

25. veebr 2026, 23:45 UTC

Tulu

Ferrovial 4Q Rev EUR2.72B >FER.MC

25. veebr 2026, 23:42 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25. veebr 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Company's Business Operations Remain Normal >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY EPS CNY47.67 >TCOM

25. veebr 2026, 23:06 UTC

Tulu

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25. veebr 2026, 23:01 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25. veebr 2026, 22:56 UTC

Market Talk
Tulu

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25. veebr 2026, 22:43 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25. veebr 2026, 22:40 UTC

Market Talk
Tulu

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25. veebr 2026, 22:40 UTC

Tulu

Karoon Energy Says Search for New CFO Well Advanced

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says CFO Ray Church to Leave Company

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25. veebr 2026, 22:38 UTC

Tulu

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat